Polaris Market Research today announced findings from its latest report, projecting the global Superdisintegrants Market to grow from USD 439.25 million in 2023 to USD 829.54 million by 2032, at a CAGR of 7.3% from 2024 to 2032. The report covers 10 key companies across four segmentation categories: product, formulation, therapeutic area, and region.

Analyst Commentary on Superdisintegrants Market Growth

“Patients increasingly prefer tablets that dissolve quickly and are easy to swallow, and that preference is making superdisintegrants a core ingredient in modern oral solid dose formulation,” said the Polaris Market Research analyst team. “The opportunity for buyers and investors lies with excipient suppliers that offer high-performance crospovidone and other grades tailored to orally disintegrating tablets and the expanding generics market.”

Superdisintegrants Market Statistics at a Glance

• 2023 Market Size: USD 439.25 million
• 2024 Market Estimate: USD 470.7 million
• 2032 Projected Size: USD 829.54 million
• CAGR (2024-2032): 7.3%
• Largest Region (2022): North America

Key Growth Drivers, Major Companies and Segments Covered

Growth Drivers: Growing adoption of orally disintegrating tablets (ODTs), a rising prevalence of chronic diseases, and an expanding generics market are the primary forces behind the market's expansion, alongside growing demand for novel drug delivery systems. Superdisintegrants help tablets break down quickly, improving drug absorption and bioavailability, and ODTs are gaining traction in neurology, psychiatry, and pain management because of faster onset of action and better patient compliance. In July 2021, SPI Pharma launched UltraBurst, an excipient platform for flash ODTs that allows disintegration in less than 10 seconds. Safety and quality concerns remain a challenge. Superdisintegrants are widely used across the pharmaceutical industry, which is growing on rising demand for healthcare products and new drug development.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/superdisintegrants-market

Segment Highlights: Crospovidone is projected to grow fastest, helped by a wide range of grades including high-performing options for ODTs and fast-dissolving tablets. Tablets held the largest formulation share in 2022 as the most used dosage form in the pharmaceutical industry. Gastrointestinal diseases are expected to hold a significant revenue share, with research cited on the report page suggesting that around 20% of people globally are affected by GERD. Natural mucilage is also being explored in drug delivery systems because it is accessible, lower in cost, and chemically inert.

Competitive Landscape: Chemical and excipient specialists such as BASF, Roquette Freres, Ashland Global, DFE Pharma, and Asahi Kasei compete alongside Dow DuPont, Merck, and JRS Pharma. Competition centers on new grades, natural and starch-based ranges, and ODT-focused excipient platforms. Demand for fast-dissolving tablets is further supported by the growing generics market, since many generic medicines are formulated for rapid dissolution and absorption.

Major Companies Covered: BASF, Roquette Freres, Ashland Global, Dow DuPont, DFE Pharma, Asahi Kasei, Merck, and JRS Pharma, among others.

Segments Covered: By Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), By Formulation (Tablets, Capsules), By Therapeutic Area (Gastrointestinal, Neurological, Oncology, Infectious, Cardiovascular, Hematological, and Inflammatory Diseases), By Region.

Recent Developments in the Superdisintegrants Market

• January 2022: DFE Pharma, a Germany-based excipient developer, introduced a new maize starch range for its Nutrofeli excipients for its nutraceuticals business.
• July 2021: SPI Pharma launched UltraBurst, an excipient platform for flash orally disintegrating tablets that allows disintegration in less than 10 seconds.

Regional Snapshot: North America Leads, Asia Pacific Shows Significant Growth

North America held the largest revenue share in 2022 and is expected to maintain its position, supported by advances in drug delivery systems such as sublingual and buccal formulations that rely on rapid disintegration. Asia Pacific registered a significant growth rate in 2022 and is projected to sustain it, as the growing pharmaceutical industry in China, home to about 4,500 pharmaceutical firms, fuels demand for oral solid dosage forms and more effective drug delivery systems. BeiGene, for example, operates in China as well as the U.S., Europe, and Australia and is running more than 90 clinical trials for roughly 30 medications. Sublingual and buccal delivery systems offer faster onset of action and improved bioavailability compared with standard oral administration.

Why It Matters for Stakeholders Tracking the Superdisintegrants Market Forecast to 2032

For stakeholders researching the superdisintegrants market forecast, the underlying report benchmarks Superdisintegrants market share, company positioning, and segment-level forecasts to support sourcing, partnership, and investment decisions through 2032. It also includes Porter's Five Forces, PESTEL, value chain, and COVID-19 impact analysis, plus country-level data across five regions. Product coverage includes modified starch, modified cellulose, crospovidone, and ion exchange resin, giving buyers a clear view of which excipient types are gaining share.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

animal-feed-market

graphite-market

experience-travel-services-market

functional-water-benefits-types-market

lithium-ion-battery-market

europe-chemical-distribution-market

adventure-tourism-market

profiling-top-10-firms-in-the-connected-cars-market-2025

ot-firewall-market